Further analysis of this hPSC-based model may identify fetal-specific vulnerabilities in ETV6-RUNX1 ALL, informing new and more specific therapeutic targets, which could be tested within this tractable platform. This evidence concerns the gene ETV6 and acute lymphoblastic leukemia.